<DOC>
	<DOCNO>NCT00467870</DOCNO>
	<brief_summary>To evaluate pharmacokinetics TU 750 mg TU 1000 mg via multiple measurement serum total testosterone .</brief_summary>
	<brief_title>Long-term Safety Study Intramuscular Injections 750 mg 1000 mg Testosterone Undecanoate Hypogonadal Men</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male primary secondary hypogonadism least 18 year age study part C2 weigh ≥143.3 lb ( ≥65 kg ) Morning screen serum testosterone concentration &lt; 300 ng/dL American Urological Association ( AUA ) Symptom Score ≥15 significant prostatic symptom History carcinoma , tumor induration prostate male mammary gland include suspicion thereof Screening serum prostatespecific antigen ( PSA ) level &gt; 4 ng/mL hyperplasia prostate ( size &gt; 75 cm3 measure transrectal ultrasonography ) Past present liver tumor acute chronic hepatic disease impairment liver function ; liver function test ( alanine aminotransferase [ ALT ] , aspartate aminotransferase [ AST ] ) exceed 1.5 time upper limit normal History deep vein thrombosis past 5 year history cerebrovascular accident Severe acne Hypertension ( systolic blood pressure &gt; 160 mm Hg diastolic blood pressure &gt; 95 mm Hg ) coronary heart disease stabilize therapy assess investigator Insulindependent diabetes mellitus uncontrolled noninsulindependent diabetes mellitus ; patient diabetes excluded screening glycated hemoglobin ( HbA1C ) level &gt; 9 % Use sex hormone within 28 day ( injectable testosterone preparation ) 7 day ( oral , gel , patch , etc , testosterone preparation ) prior screen visit throughout study ( exclusive administer study drug ) Use steroidal anabolic drug supplement ( eg , dehydroepiandrosterone [ DHEA ] ) application method within 28 day prior first administration study drug throughout study ( exclusive administrate study drug ) Medication substance might interfere testosterone metabolism within 28 day first administration study drug History sleep apnea Insulindependent diabetes mellitus Use steroidal anabolic drug supplement application method within 28days prior first administration study drug throughout study ( exclusive administer study drug )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>investigational</keyword>
	<keyword>testosterone</keyword>
	<keyword>testosterone undecanoate</keyword>
	<keyword>TU</keyword>
	<keyword>Hypogonadism</keyword>
	<keyword>primary hypogonadism</keyword>
	<keyword>secondary hypogonadism</keyword>
</DOC>